Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.

Miyagawa I, Nakano K, Iwata S, Nakayamada S, Saito K, Hanami K, Fukuyo S, Kubo S, Kawabe A, Miyazaki Y, Tanaka Y.

Arthritis Res Ther. 2019 Jun 22;21(1):151. doi: 10.1186/s13075-019-1933-8.

2.

Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.

Ishikawa Y, Iwata S, Hanami K, Nawata A, Zhang M, Yamagata K, Hirata S, Sakata K, Todoroki Y, Nakano K, Nakayamada S, Satoh M, Tanaka Y.

Arthritis Res Ther. 2018 Oct 26;20(1):240. doi: 10.1186/s13075-018-1737-2.

3.

Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.

Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo S, Inoue Y, Ueno M, Tanaka Y.

Int J Rheum Dis. 2019 Mar;22(3):434-442. doi: 10.1111/1756-185X.13387. Epub 2018 Oct 18.

PMID:
30338639
4.

Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching.

Kubo S, Nakayamada S, Nakano K, Sawamukai N, Hirata S, Hanami K, Saito K, Tanaka Y.

Clin Immunol. 2018 Jun;191:67-74. doi: 10.1016/j.clim.2018.03.018. Epub 2018 Mar 31.

PMID:
29614335
5.

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.

Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y.

Lupus. 2018 Apr;27(5):802-811. doi: 10.1177/0961203317749047. Epub 2018 Jan 7.

PMID:
29308726
6.

Pleurisy Caused by Mycobacterium abscessus in a Young Patient with Dermatomyositis: A Case Report and Brief Review of the Literature.

Noguchi S, Hanami K, Miyata H, Torii R, Shimabukuro I, Kubo S, Obata H, Yoshii C, Yatera K.

Intern Med. 2018 Apr 1;57(7):997-1002. doi: 10.2169/internalmedicine.9537-17. Epub 2017 Dec 21. Review.

7.

Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients.

Kubo S, Nakayamada S, Yoshikawa M, Miyazaki Y, Sakata K, Nakano K, Hanami K, Iwata S, Miyagawa I, Saito K, Tanaka Y.

Arthritis Rheumatol. 2017 Oct;69(10):2029-2037. doi: 10.1002/art.40180. Epub 2017 Aug 25.

8.

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.

Hirata S, Li W, Kubo S, Fukuyo S, Mizuno Y, Hanami K, Sawamukai N, Yamaoka K, Saito K, Defranoux NA, Tanaka Y.

Mod Rheumatol. 2016 Nov;26(6):850-856. doi: 10.3109/14397595.2016.1153449. Epub 2016 Mar 30.

PMID:
26873570
9.
10.

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.

Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, Hanami K, Saito K, Tanaka Y.

Ann Rheum Dis. 2016 Jul;75(7):1321-7. doi: 10.1136/annrheumdis-2015-207784. Epub 2015 Aug 5.

PMID:
26245754
11.

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.

Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K.

Ann Rheum Dis. 2015 Feb;74(2):389-95. doi: 10.1136/annrheumdis-2013-204016. Epub 2013 Nov 28. Erratum in: Ann Rheum Dis. 2016 Jul;75(7):e46.

12.

Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.

Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H.

Mod Rheumatol. 2014 May;24(3):399-404. doi: 10.3109/14397595.2013.843757. Epub 2013 Nov 5.

PMID:
24252045
13.

Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.

Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.

Mod Rheumatol. 2014 May;24(3):405-9. doi: 10.3109/14397595.2013.844294. Epub 2013 Oct 21.

PMID:
24252016
14.

Dopamine D2-like receptor signaling suppresses human osteoclastogenesis.

Hanami K, Nakano K, Saito K, Okada Y, Yamaoka K, Kubo S, Kondo M, Tanaka Y.

Bone. 2013 Sep;56(1):1-8. doi: 10.1016/j.bone.2013.04.019. Epub 2013 Apr 28.

PMID:
23631878
15.

[Dopamine receptor signaling regulates human osteoclastogenesis].

Hanami K, Nakano K, Tanaka Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(1):35-9. Review. Japanese.

16.

A novel flow-injection analysis system for evaluation of antioxidants by using sodium dichloroisocyanurate as a source of hypochlorite anion.

Ichiba H, Hanami K, Yagasaki K, Tanaka M, Ito H, Fukushima T.

Drug Discov Ther. 2012 Feb;6(1):44-8.

17.

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study.

Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Sato E, Saito K, Kaneko Y, Fukuyo S, Kurasawa T, Hanami K, Kameda H, Yamanaka H.

Rheumatology (Oxford). 2011 Oct;50(10):1908-15. doi: 10.1093/rheumatology/ker221. Epub 2011 Jul 13.

18.

Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis.

Hiura M, Abe S, Tabaru A, Shimajiri S, Hanami K, Saito K, Tanaka Y, Harada M.

Hepatol Res. 2011 May;41(5):492-6. doi: 10.1111/j.1872-034X.2011.00793.x. Epub 2011 Mar 21.

PMID:
21435128
19.

Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model.

Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, Tanaka S, Katsuki I, Matsushita S, Tanaka Y.

J Immunol. 2011 Mar 15;186(6):3745-52. doi: 10.4049/jimmunol.1002475. Epub 2011 Feb 9.

20.

Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.

Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, Hanami K, Fukuyo S, Miyagawa I, Kubo S, Tanaka Y.

J Rheumatol. 2011 Apr;38(4):633-41. doi: 10.3899/jrheum.100729. Epub 2010 Dec 15.

PMID:
21159836
21.

Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.

Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, Tanaka Y.

Mod Rheumatol. 2011 Apr;21(2):184-91. doi: 10.1007/s10165-010-0370-y. Epub 2010 Nov 5.

PMID:
21052764
22.

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).

Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, Takeuchi T.

Mod Rheumatol. 2011 Apr;21(2):122-33. doi: 10.1007/s10165-010-0366-7. Epub 2010 Oct 16.

23.

A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate.

Yamaoka K, Saito K, Hanami K, Nakayamada S, Nawata M, Iwata S, Azuma T, Tanaka Y.

Mod Rheumatol. 2007;17(2):144-7. Epub 2007 Apr 20.

PMID:
17437170
24.

Glassy cell carcinoma of the cervix: cytologic features and expression of estrogen receptor, progesterone receptor and Her2/neu protein.

Kuroda H, Toyozumi Y, Masuda T, Ougida T, Hanami K, Kyoko K, Tamaru J, Itoyama S.

Acta Cytol. 2006 Jul-Aug;50(4):418-22.

PMID:
16901007
25.
26.
27.

Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study.

Yamazaki K, Yajima T, Nagao T, Shinkawa H, Kondo F, Hanami K, Asoh A, Sugano I, Ishida Y.

Pathol Res Pract. 2003;199(1):23-8.

PMID:
12650514
28.

Expression of p21/WAF-1, status of apoptosis and p53 mutation in esophageal squamous cell carcinoma with HPV infection.

Hasegawa M, Ohoka I, Yamazaki K, Hanami K, Sugano I, Nagao T, Asoh A, Wada N, Nagao K, Ishida Y.

Pathol Int. 2002 Jul;52(7):442-50.

PMID:
12167102

Supplemental Content

Loading ...
Support Center